Profound Medical Corp
TSX:PRN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Profound Medical Corp
Net Issuance of Debt
Profound Medical Corp
Net Issuance of Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Issuance of Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Profound Medical Corp
TSX:PRN
|
Net Issuance of Debt
-$290k
|
CAGR 3-Years
7%
|
CAGR 5-Years
50%
|
CAGR 10-Years
N/A
|
|
|
VentriPoint Diagnostics Ltd
XTSX:VPT
|
Net Issuance of Debt
CA$911.3k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-2%
|
CAGR 10-Years
N/A
|
|
|
Theralase Technologies Inc
XTSX:TLT
|
Net Issuance of Debt
-CA$35.9k
|
CAGR 3-Years
3%
|
CAGR 5-Years
11%
|
CAGR 10-Years
N/A
|
|
|
MedMira Inc
XTSX:MIR
|
Net Issuance of Debt
CA$148.2k
|
CAGR 3-Years
-31%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
O
|
Ondine Biomedical Inc
LSE:OBI
|
Net Issuance of Debt
CA$23.7m
|
CAGR 3-Years
57%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Conavi Medical Corp
XTSX:CNVI
|
Net Issuance of Debt
-$1.6m
|
CAGR 3-Years
-40%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Profound Medical Corp
Glance View
Profound Medical Corp. develops, manufactures and markets therapeutic platforms that combine real-time magnetic resonance imaging with directional and focused ultrasound technology for incision-free ablation of diseased tissue. The company is headquartered in Mississauga, Ontario and currently employs 146 full-time employees. The company went IPO on 2014-09-24. The firm is commercializing TULSA-PRO, which is a technology that combines real-time magnetic resonance imaging (MRI), transurethral ultrasound and closed-loop temperature feedback control. TULSA-PRO is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while protecting the urethra and rectum to help preserve the patient’s natural functional abilities. The firm is also commercializing Sonalleve, which is a therapeutic platform for the treatment of uterine fibroids and palliative pain treatment of bone metastases.
See Also
What is Profound Medical Corp's Net Issuance of Debt?
Net Issuance of Debt
-290k
USD
Based on the financial report for Dec 31, 2025, Profound Medical Corp's Net Issuance of Debt amounts to -290k USD.
What is Profound Medical Corp's Net Issuance of Debt growth rate?
Net Issuance of Debt CAGR 5Y
50%
Over the last year, the Net Issuance of Debt growth was 89%. The average annual Net Issuance of Debt growth rates for Profound Medical Corp have been 7% over the past three years , 50% over the past five years .
